Abiopharma

🔍 Xie Jian (Executive)

Company: Fulgent Genetics, Inc. (FLGT)

Report Date: 2026-04-26

Detailed Transactions and Holdings:

• Sold 4,361 shares of Common Stock at $16.31 per share (Direct)
  Date: 2026-04-26 | Code: F | equity_swap_involved: false | shares_owned_after: 370,952.00 | transaction_form_type: 4 | Footnotes: F1
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-04-26 | Code: H | nature_of_ownership: By Trust | shares_owned_after: 220,816.00 | Footnotes: F2

Footnotes:

• F1: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units assumed pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 by and among Fulgent Genetics, Inc., FG Merger Sub, Inc., Fulgent Pharma Holdings, Inc., and the stockholders listed therein. These awards were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022.
• F2: Securities held by The Hsieh Family Dynasty Trust, dated January 27, 2010 (the "Trust"). Mr. Xie serves on the investment committee of the Trust. Mr. Xie disclaims any beneficial interest except with respect to any pecuniary interest therein.